Trial Profile
A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; RGT 100 (Primary) ; RGT 100 (Primary) ; RGT 100 (Primary)
- Indications Liver metastases; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 25 Aug 2021 Status changed from completed to discontinued.
- 10 Mar 2021 Status changed from active, no longer recruiting to completed.
- 20 Jan 2021 Planned End Date changed from 26 Jan 2021 to 23 Mar 2021.